Save time and get answers to complex questions with AI chat
Tenofovir generic patent?Allergan's patent for latisse expired?Xiaflex market launch year?Zemdri nce gain exclusivity 2028 patent 2031?Somatuline generic name?
See the DrugPatentWatch profile for vascepa
Vascepa (icosapent ethyl) is contraindicated in patients with known hypersensitivity to icosapent ethyl or any component of the capsule. This includes severe allergic reactions like anaphylaxis.[1]
Avoid Vascepa in pregnancy due to potential fetal harm—animal studies show embryocidal and teratogenic effects at doses similar to human levels. Use only if benefits outweigh risks, and enroll in the pregnancy exposure registry (1-877-311-8972). It is unknown if Vascepa passes into breast milk; weigh risks before nursing.1
Do not use in patients with severe hepatic impairment (Child-Pugh C), as safety and efficacy are unestablished. No specific contraindication for severe kidney disease, but monitor closely, especially with other lipid-altering drugs.[1]
Patients with active pathological bleeding or hemorrhagic stroke should not take Vascepa, due to increased bleeding risk from its antithrombotic effects. Use caution with anticoagulants (e.g., warfarin) or antiplatelets (e.g., aspirin), as it may prolong bleeding time.1
Other Questions About Vascepa :